Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Frontera Therapeutics
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...